Access cutting-edge triple negative breast cancer treatment through this clinical trial at a research site in Oakland. Study-provided care at no cost to qualified participants.
Access triple negative breast cancer specialists in Oakland at no cost
This study follows strict safety protocols and ethical guidelines
All study-related triple negative breast cancer treatment provided free
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this triple negative breast cancer clinical trial in Oakland, CA
If you're searching for triple negative breast cancer treatment options in Oakland, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Oakland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced triple negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.